NewSquare Capital LLC Purchases New Position in Zoetis Inc. (NYSE:ZTS)

NewSquare Capital LLC acquired a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 350 shares of the company’s stock, valued at approximately $69,000.

Several other large investors have also bought and sold shares of ZTS. River Street Advisors LLC raised its position in shares of Zoetis by 3.4% in the 4th quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after acquiring an additional 58 shares in the last quarter. Perigon Wealth Management LLC grew its stake in Zoetis by 0.3% in the fourth quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock worth $4,654,000 after purchasing an additional 59 shares during the period. TFC Financial Management Inc. raised its holdings in Zoetis by 3.3% in the third quarter. TFC Financial Management Inc. now owns 1,918 shares of the company’s stock worth $334,000 after purchasing an additional 61 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in Zoetis by 5.0% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,281 shares of the company’s stock valued at $253,000 after buying an additional 61 shares during the period. Finally, Townsend Asset Management Corp NC ADV boosted its holdings in shares of Zoetis by 0.3% during the 3rd quarter. Townsend Asset Management Corp NC ADV now owns 22,585 shares of the company’s stock valued at $3,929,000 after buying an additional 66 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the transaction, the executive vice president now directly owns 20,417 shares in the company, valued at $4,037,257.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 2,209 shares of company stock valued at $371,293 in the last 90 days. Company insiders own 0.15% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on ZTS shares. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Barclays lowered their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday. Piper Sandler restated an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Stifel Nicolaus lowered their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Finally, The Goldman Sachs Group lifted their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $218.00.

Zoetis Stock Performance

ZTS stock traded up $1.37 during trading on Wednesday, reaching $150.93. The stock had a trading volume of 2,281,466 shares, compared to its average volume of 3,057,324. The stock’s 50 day moving average is $173.78 and its two-hundred day moving average is $179.78. The firm has a market cap of $69.03 billion, a PE ratio of 29.75, a PEG ratio of 2.22 and a beta of 0.85. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). The business had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. Zoetis’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter last year, the company earned $1.15 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 5.79 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.14%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s payout ratio is 34.12%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.